1. TIOMAX: A Spanish Multicenter Registry of the real-world use of the TItanium OptiMAX
- Author
-
José R, López-Mínguez, Juan M, Nogales-Asensio, Sebastián, Romani, Fernando, Rivero-Crespo, Victor M, Aragón-Extremera, Jesús M, Jiménez-Mazuecos, Fernando, Carrasco, Juan Francisco, Oteo-Domínguez, Francisco, Bosa-Ojeda, and Joan A, Gómez-Hospital
- Subjects
Male ,Time Factors ,Coronary Thrombosis ,Coronary Artery Disease ,Middle Aged ,Prosthesis Design ,Prosthesis Failure ,Treatment Outcome ,Risk Factors ,Spain ,Humans ,Female ,Stents ,Chromium Alloys ,Prospective Studies ,Registries ,Acute Coronary Syndrome ,Angioplasty, Balloon, Coronary ,Aged - Abstract
To compare the safety and efficacy of the new cobalt-chromium bioactive stent Titan OptimaxThe TIOMAX registry includes 784 patients who underwent percutaneous coronary intervention with these stents in 21 Spanish hospitals.Analysis of all patients in the registry without exclusion criteria, candidates for revascularization (March-2013/July-2014). Initially 273 patients received Titan-2Mean age was 65.8 ± 13.0 (78.1% men); 49.2% were STEACS patients (n = 322), 29.8% NSTEACS, and 27.3% had stable angina or silent ischemia. Most STEACS patients (76.4% of n = 322) were treated24 hr after developing symptoms. All-cause death (D), cardiac death (CD), acute myocardial infarction (AMI), and stent thrombosis (ST) at 1 month were 1.1, 0.8, 0.1, and 0.5%, respectively, with no significant differences between groups. At 1 year, the death rate was 5.5% for Titan-2 vs. 4.1% for OptimaxThe Titan Optimax retains the efficacy and safety of Titan 2. It appears to perform better in the subgroup of STEACS patients, by reducing the non-fatal CE of AMI/ST/TLR.
- Published
- 2017